Noiafren (Clobazam)

Clobazam, the active ingredient in Noiafren, is a benzodiazepine presented as an oral tablet for oral use. It is employed as an adjunctive therapy to reduce seizure frequency in patients with epilepsy who have not achieved control with other medications. The medication is indicated for use in combination with other antiepileptic drugs and is regulated as a Schedule IV controlled substance in the European Union.

GNH USA supplies Noiafren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clobazam is used as an adjunctive anticonvulsant in several seizure‑related conditions.

- Adjunctive therapy for seizures: reduces frequency of refractory seizures when added to existing antiepileptic regimens. - Lennox‑Gastaut syndrome: helps control multiple seizure types in this severe childhood epilepsy. - Partial‑onset seizures: improves seizure control in patients with focal epilepsy not fully managed by other drugs.

Clobazam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: light‑headed sensation, especially when standing quickly. - Ataxia: impaired coordination and unsteady gait. - Cognitive slowing: reduced concentration and slowed thinking.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, particularly with other depressants. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

When prescribing or dispensing Clobazam, several safety considerations are essential.

- Pregnancy: Category D – potential risk to the fetus; use only if benefits outweigh risks. - Concomitant CNS depressants: avoid additive sedation and respiratory depression. - Abrupt discontinuation: may precipitate withdrawal seizures; taper gradually under medical supervision. - Elderly patients: increased susceptibility to falls and cognitive impairment. - Hepatic impairment: monitor for enhanced drug exposure and adjust therapy as needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Clobazam interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Other benzodiazepines: additive sedation and respiratory depression. - Opioids: heightened risk of profound CNS depression. - Alcohol: synergistic sedative effects may impair respiration.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase clobazam plasma concentrations. - Antidepressants (SSRIs, SNRIs): potential for enhanced CNS effects. - Other antiepileptics (phenytoin, carbamazepine): may alter clobazam metabolism and efficacy.